On June 30, 2011, I purchased shares of Cooper Companies (COO
) for my Covestor Healthcare Model at a cost basis of $80.62. Cooper has been a company I have admired for the most part from a distance and in fact first reviewed the stock almost 8 years ago on September 1, 2004. Cooper closed at $80.08, down $(.55) or (.68)% on the day. Let's take a closer look at this stock and update my review.
According to the Yahoo "Profile" on Cooper, the company
"... through its subsidiaries, develops, manufactures, and markets healthcare products serving the vision care and women's healthcare markets worldwide. It offers a range of soft contact lenses for the vision care market, such as toric lenses, which correct astigmatism; multifocal lenses for presbyopia; and spherical lenses that correct the common visual defects. The company also provides aspheric lenses for near and farsightedness. In addition, it engages in the development, manufacture, and marketing of medical devices, diagnostic products, and surgical instruments and accessories used primarily by gynecologists and obstetricians."
On June 3, 2011, Cooper (COO) reported 2nd quarter 2011 results. For the quarter ended April 30, 2011, the company reported revenue of $325.3 million, an 8% increase (in constant currency) exceeding the Zacks estimates of $315 million. The company reported adjusted earnings per share of $1.02, exceeding expectations by Zacks of $.93/share and outperforming the year-ago earnings result of $.61/share.
To top off the fabulous quarterly report, the company raised guidance for fiscal 2011 to a higher range of $3.90 to $4.05/share vs.